- Home
- INM vs IXHL Comparison
INM vs IXHL Comparison
Compare INM & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- IXHL
- Stock Information
- Founded
- INM 1981
- IXHL 2001
- Country
- INM Canada
- IXHL Australia
- Employees
- INM N/A
- IXHL N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- IXHL
- Sector
- INM Health Care
- IXHL
- Exchange
- INM Nasdaq
- IXHL Nasdaq
- Market Cap
- INM 3.2M
- IXHL 3.6M
- IPO Year
- INM N/A
- IXHL N/A
- Fundamental
- Price
- INM $2.95
- IXHL $0.26
- Analyst Decision
- INM
- IXHL
- Analyst Count
- INM 0
- IXHL 0
- Target Price
- INM N/A
- IXHL N/A
- AVG Volume (30 Days)
- INM 214.0K
- IXHL 109.6M
- Earning Date
- INM 05-27-2025
- IXHL 05-15-2025
- Dividend Yield
- INM N/A
- IXHL N/A
- EPS Growth
- INM N/A
- IXHL N/A
- EPS
- INM N/A
- IXHL N/A
- Revenue
- INM $4,920,990.00
- IXHL $98,000.00
- Revenue This Year
- INM N/A
- IXHL $3,817.06
- Revenue Next Year
- INM N/A
- IXHL $66.67
- P/E Ratio
- INM N/A
- IXHL N/A
- Revenue Growth
- INM N/A
- IXHL N/A
- 52 Week Low
- INM $1.72
- IXHL $0.12
- 52 Week High
- INM $15.70
- IXHL $3.55
- Technical
- Relative Strength Index (RSI)
- INM 53.78
- IXHL 45.37
- Support Level
- INM $2.08
- IXHL $0.24
- Resistance Level
- INM $4.00
- IXHL $1.06
- Average True Range (ATR)
- INM 0.35
- IXHL 0.12
- MACD
- INM 0.01
- IXHL 0.04
- Stochastic Oscillator
- INM 45.31
- IXHL 18.37
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.